fgf bp1 Search Results


fgfbp1  (Proteintech)
93
Proteintech fgfbp1
Fgfbp1, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf+bp1/pmc12278513__40779_2025_618_MOESM1_ESM-31-19-21?v=Proteintech
Average 93 stars, based on 1 article reviews
fgfbp1 - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
fgfbp1 elisa kit  (Boster Bio)
91
Boster Bio fgfbp1 elisa kit
( A ) Differential proteomic analysis of tumor tissues obtained from bevacizumab-sensitive and -resistant HCT116 CRCLM xenografts (log 2 [fold change] > 1.0, P < 0.05; n = 3). ( B ) Immunohistochemical staining and quantification of <t>FGFBP1</t> in the tumor-liver interface of CRCLM xenografts ( n = 6). Scale bar: 50 μm. ( C and D ) Western blotting ( C ) and ELISA ( D ) analysis of the expression of FGFBP1 in HCT116 and HT-29 cells isolated from the indicated CRCLM xenografts ( n = 3). ( E ) H&E staining of the tumor-liver interface of CRCLM xenografts. Scale bar: 100 μm. Quantification of RHGP is shown ( n = 6). ( F ) Immunofluorescence staining of the EpCAM + tumor cells (green) that infiltrated the liver parenchyma and hijacked the CD31 + sinusoidal blood vessels (red) in the tumor-liver interface of CRCLM xenografts. Scale bar: 20 μm. Quantification of the co-opted sinusoidal blood vessels is shown ( n = 6). ( G ) Immunofluorescence staining of FAPα + HSCs (green) attached to the CD31 + sinusoidal blood vessels (red) in the tumor-liver interface of CRCLM xenografts. Scale bar: 10 μm. Quantification of the co-opted FAPα + HSCs is shown ( n = 6). Dotted lines indicate the tumor-liver interface. LM, liver metastases; T, tumor; L, liver. Data are presented as mean ± SEM. NS, no significance. *** P < 0.001 (2-tailed, unpaired t test).
Fgfbp1 Elisa Kit, supplied by Boster Bio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fgf+bp1/pmc09525122-269-1-4?v=Boster+Bio
Average 91 stars, based on 1 article reviews
fgfbp1 elisa kit - by Bioz Stars, 2026-07
91/100 stars
  Buy from Supplier

Image Search Results


( A ) Differential proteomic analysis of tumor tissues obtained from bevacizumab-sensitive and -resistant HCT116 CRCLM xenografts (log 2 [fold change] > 1.0, P < 0.05; n = 3). ( B ) Immunohistochemical staining and quantification of FGFBP1 in the tumor-liver interface of CRCLM xenografts ( n = 6). Scale bar: 50 μm. ( C and D ) Western blotting ( C ) and ELISA ( D ) analysis of the expression of FGFBP1 in HCT116 and HT-29 cells isolated from the indicated CRCLM xenografts ( n = 3). ( E ) H&E staining of the tumor-liver interface of CRCLM xenografts. Scale bar: 100 μm. Quantification of RHGP is shown ( n = 6). ( F ) Immunofluorescence staining of the EpCAM + tumor cells (green) that infiltrated the liver parenchyma and hijacked the CD31 + sinusoidal blood vessels (red) in the tumor-liver interface of CRCLM xenografts. Scale bar: 20 μm. Quantification of the co-opted sinusoidal blood vessels is shown ( n = 6). ( G ) Immunofluorescence staining of FAPα + HSCs (green) attached to the CD31 + sinusoidal blood vessels (red) in the tumor-liver interface of CRCLM xenografts. Scale bar: 10 μm. Quantification of the co-opted FAPα + HSCs is shown ( n = 6). Dotted lines indicate the tumor-liver interface. LM, liver metastases; T, tumor; L, liver. Data are presented as mean ± SEM. NS, no significance. *** P < 0.001 (2-tailed, unpaired t test).

Journal: The Journal of Clinical Investigation

Article Title: Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models

doi: 10.1172/JCI157399

Figure Lengend Snippet: ( A ) Differential proteomic analysis of tumor tissues obtained from bevacizumab-sensitive and -resistant HCT116 CRCLM xenografts (log 2 [fold change] > 1.0, P < 0.05; n = 3). ( B ) Immunohistochemical staining and quantification of FGFBP1 in the tumor-liver interface of CRCLM xenografts ( n = 6). Scale bar: 50 μm. ( C and D ) Western blotting ( C ) and ELISA ( D ) analysis of the expression of FGFBP1 in HCT116 and HT-29 cells isolated from the indicated CRCLM xenografts ( n = 3). ( E ) H&E staining of the tumor-liver interface of CRCLM xenografts. Scale bar: 100 μm. Quantification of RHGP is shown ( n = 6). ( F ) Immunofluorescence staining of the EpCAM + tumor cells (green) that infiltrated the liver parenchyma and hijacked the CD31 + sinusoidal blood vessels (red) in the tumor-liver interface of CRCLM xenografts. Scale bar: 20 μm. Quantification of the co-opted sinusoidal blood vessels is shown ( n = 6). ( G ) Immunofluorescence staining of FAPα + HSCs (green) attached to the CD31 + sinusoidal blood vessels (red) in the tumor-liver interface of CRCLM xenografts. Scale bar: 10 μm. Quantification of the co-opted FAPα + HSCs is shown ( n = 6). Dotted lines indicate the tumor-liver interface. LM, liver metastases; T, tumor; L, liver. Data are presented as mean ± SEM. NS, no significance. *** P < 0.001 (2-tailed, unpaired t test).

Article Snippet: An FGFBP1 ELISA Kit (Boster) and CXCL5 ELISA Kit (Solarbio) were used to measure FGFBP1 or CXCL5 levels in the cell culture supernatant according to the manufacturers’ instructions.

Techniques: Immunohistochemical staining, Staining, Western Blot, Enzyme-linked Immunosorbent Assay, Expressing, Isolation, Immunofluorescence

( A ) CT scan images of CRCLM patients with DHGP or PHGP treated preoperatively with Chemo or Bev+Chemo, and red arrows indicate the tumor lesions. Quantification of the morphologic response to RHGP is shown. ( B ) H&E staining of the tumor-liver interface of human CRCLM tissues. Quantification of RHGP is shown ( n = 6). Scale bar: 100 μm. ( C ) Immunohistochemical staining of FGFBP1 in the tumor-liver interface of human CRCLM tissues. Scale bar: 20 μm. Quantification of FGFBP1 staining is shown (right panel, n = 6). ( D ) Immunofluorescence staining of the EpCAM + cancer cells (green) that infiltrated the liver parenchyma and hijacked the CD31 + sinusoidal blood vessels (red), and FAPα (gray) expression in the co-opted HSCs in the tumor-liver interface of human CRCLM tissues. Scale bar: 20 μm. Quantification of the co-opted sinusoidal blood vessels and FAPα + HSCs is shown ( n = 6). Yellow arrows indicate the FAPα + HSCs. ( E ) Immunofluorescence staining of p-FGFR1(green) in HSCs attached to the CD31 + sinusoidal blood vessels (red) in the tumor-liver interface of human CRCLM tissues. Scale bar: 20 μm. White arrows indicate the p-FGFR1 + HSCs. ( F ) Pearson’s correlation analysis of FAPα + HSCs and the co-opted sinusoidal blood vessels, percentage of RHGP, or FGFBP1 expression in human CRCLM tissues ( n = 82). ( G ) CT scan images of CRCLM patients with RHGP treated preoperatively with Chemo or Bev+Chemo, and red arrows indicate the tumor lesions. Quantification of the change of tumor burden is shown. Dotted lines indicate the tumor-liver interface. Chemo, chemotherapy; Bev, bevacizumab; T, tumor; L, liver. Data are presented as mean ± SEM. NS, no significance. ** P < 0.01, *** P < 0.001 (2-tailed, unpaired t test).

Journal: The Journal of Clinical Investigation

Article Title: Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models

doi: 10.1172/JCI157399

Figure Lengend Snippet: ( A ) CT scan images of CRCLM patients with DHGP or PHGP treated preoperatively with Chemo or Bev+Chemo, and red arrows indicate the tumor lesions. Quantification of the morphologic response to RHGP is shown. ( B ) H&E staining of the tumor-liver interface of human CRCLM tissues. Quantification of RHGP is shown ( n = 6). Scale bar: 100 μm. ( C ) Immunohistochemical staining of FGFBP1 in the tumor-liver interface of human CRCLM tissues. Scale bar: 20 μm. Quantification of FGFBP1 staining is shown (right panel, n = 6). ( D ) Immunofluorescence staining of the EpCAM + cancer cells (green) that infiltrated the liver parenchyma and hijacked the CD31 + sinusoidal blood vessels (red), and FAPα (gray) expression in the co-opted HSCs in the tumor-liver interface of human CRCLM tissues. Scale bar: 20 μm. Quantification of the co-opted sinusoidal blood vessels and FAPα + HSCs is shown ( n = 6). Yellow arrows indicate the FAPα + HSCs. ( E ) Immunofluorescence staining of p-FGFR1(green) in HSCs attached to the CD31 + sinusoidal blood vessels (red) in the tumor-liver interface of human CRCLM tissues. Scale bar: 20 μm. White arrows indicate the p-FGFR1 + HSCs. ( F ) Pearson’s correlation analysis of FAPα + HSCs and the co-opted sinusoidal blood vessels, percentage of RHGP, or FGFBP1 expression in human CRCLM tissues ( n = 82). ( G ) CT scan images of CRCLM patients with RHGP treated preoperatively with Chemo or Bev+Chemo, and red arrows indicate the tumor lesions. Quantification of the change of tumor burden is shown. Dotted lines indicate the tumor-liver interface. Chemo, chemotherapy; Bev, bevacizumab; T, tumor; L, liver. Data are presented as mean ± SEM. NS, no significance. ** P < 0.01, *** P < 0.001 (2-tailed, unpaired t test).

Article Snippet: An FGFBP1 ELISA Kit (Boster) and CXCL5 ELISA Kit (Solarbio) were used to measure FGFBP1 or CXCL5 levels in the cell culture supernatant according to the manufacturers’ instructions.

Techniques: Computed Tomography, Staining, Immunohistochemical staining, Immunofluorescence, Expressing